Evidence map›Paper›PMID 37731836›Full record

ArticleDEN open2024

Population effectiveness of endoscopy screening for mortality reduction in gastric cancer.

Naoki Ishii, Yasutoshi Shiratori, Masahiro Ishikane, Fumio Omata

2 registry-linked trialsAbstract read
In one paragraph

Article in DEN open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06316882 completednot on this map

ROGCAS - Retrospective Observational Gastric Cancer Study

TypeobservationalSponsorUnidade Local De Saúde Do Norte AlentejanoRan2023 to 2025Enrolled349ConditionsGastric Cancer, Gastric (Stomach) Cancer, Atrophic Gastritis, Intestinal Metaplasia of Gastric MucosaArmsScreening endoscopy
NCT07522320 active not recruitingnot on this mapstarted 2026, after this paper: background citation

Real-world Incremental Costs of Opportunistic Upper Gastrointestinal Endoscopy Added to Colorectal Cancer Screening and the Economic Burden of Gastric Cancer Management: a Retrospective Cohort Study - Study Protocol

Typeobservational_patient_registrySponsorUnidade Local De Saúde Do Norte AlentejanoRan2026 to 2026Enrolled250ConditionsGastric Cancer (GC), Gastric Adenocarcinoma
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Naoki IshiiDivision of Gastroenterology Tokyo Shinagawa Hospital Tokyo Japan.ORCID https://orcid.org/0000-0003-4876-1063
Yasutoshi ShiratoriDivision of Gastroenterology Maimonides Medical Center New York USA.ORCID https://orcid.org/0000-0002-7784-6210
Masahiro IshikaneDisease Control and Prevention Center National Center for Global Health and Medicine Tokyo Japan.
Fumio OmataYokohama Konandai Clinic Kanagawa Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: No randomized controlled trials have compared endoscopic screening with no screening for gastric cancer on an intention-to-screen basis, and the population-based evidence is insufficient. This study aimed to identify factors contributing to the population effectiveness of cancer screening, estimate the number needed to screen (NNS) to reduce one gastric cancer-related death, and evaluate the expected mortality-rate reduction in endoscopic screening for gastric cancer in 184 countries. Methods: Factors contributing to the attributable risk, NNS, and mortality-rate reduction were identified. A rapid review was performed in PubMed to estimate the pooled relative risk of endoscopic screening compared to that of no screening for mortality reduction. NNSs and mortality-rate reduction were estimated using the pooled relative risk and GLOBOCAN data. Results: The crude mortality rate, the effectiveness of the screening modality, and the screened rate contributed to the attributable risk, NNS, and mortality-rate reduction in cancer screening. The pooled relative risk was 0.58 in endoscopy screening compared to that in no screening. NNSs and expected mortality-rate reduction differed across countries and ranged from 2522 to 91,575 and 0.2 to 7.9 (per 100,000 individuals) for the screened rate of 20%, respectively. Conclusions: In addition to the effectiveness of the used modality, the disease burden and screened rate were important in the population effectiveness of cancer screening. Regarding the high NNSs and the low expected mortality-rate reduction, population-based endoscopic screening seems not to be effective in many countries, and these results are meaningful in decision-making regarding the introduction of endoscopic screening.

Indexed as

early detection of cancerearly diagnosisendoscopygastric cancerstomach neoplasms

Identifiers

PMID37731836
PMCPMC10508325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.